Related Experiment Video
Updated: Jul 5, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Acute migraine therapy: recent evidence from randomized comparative trials.
1Wolters Kluwer Health | Adis, Auckland, New Zealand.
Current Opinion in Neurology
|May 3, 2008
Summary
Non-steroidal anti-inflammatory drugs (NSAIDs), like aspirin, are recommended as first-line acute migraine treatments. Combination therapies, such as triptans with NSAIDs, show enhanced efficacy over single-drug approaches for migraine relief.
Area of Science:
- Neurology
- Pharmacology
Background:
- Limited adherence to International Headache Society guidelines in acute migraine treatment trials.
- Varied efficacy and tolerability profiles among available migraine therapeutics.
Purpose of the Study:
- To evaluate the comparative efficacy and tolerability of various acute migraine treatments.
- To identify optimal first-line and combination therapies for migraine management.
Main Methods:
- Systematic review and meta-analysis of clinical trials on acute migraine treatments.
- Comparative analysis of triptans, NSAIDs, and combination therapies based on efficacy and safety data.
Main Results:
- Triptans demonstrate similar efficacy, with almotriptan showing better tolerability than sumatriptan.
- Combination therapy (triptan/NSAID) is more effective than monotherapy.
- Indomethacin/caffeine/prochlorperazine combination shows comparable efficacy to triptans; further research is needed.
- Clinical benefits of triptans over aspirin or NSAIDs remain unclear.
Conclusions:
- Non-steroidal anti-inflammatory drugs (NSAIDs), particularly effervescent aspirin, are recommended as first-line acute migraine treatments.
- Multi-targeted combination therapy, like sumatriptan/naproxen sodium, offers superior efficacy compared to monotherapy.
- Further research is warranted to fully elucidate the comparative benefits of different migraine treatment strategies.
